Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

Investigational New Drugs

Volumn 33, Issue 4, 2015, Pages 881-889

  Horinouchi, Hidehito ^a   Yamamoto, Noboru ^a   Fujiwara, Yutaka ^a   Sekine, Ikuo ^a   Nokihara, Hiroshi ^a   Kubota, Kaoru ^a   Kanda, Shintaro ^a   Yagishita, Shigehiro ^a   Wakui, Hiroshi ^a   Kitazono, Satoru ^a   Mizugaki, Hidenori ^a   Tokudome, Takuto ^b   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Bristol Myers KK   (Japan)

Author keywords

Carboplatin; Ipilimumab; Japanese patients; Non small cell lung cancer; Paclitaxel; Phase I study

Indexed keywords

AMYLASE; ANTIBIOTIC AGENT; CARBOPLATIN; GAMMA GLUTAMYLTRANSFERASE; IPILIMUMAB; LEVOFLOXACIN; MEROPENEM; METHYLPREDNISOLONE; PACLITAXEL; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ADRENAL INSUFFICIENCY; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BLOOD LEVEL; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; ENTEROCOLITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTRITIS; HEMOGLOBINOPATHY; HICCUP; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPESTHESIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPARATHYROIDISM; HYPOPHOSPHATEMIA; IMMUNOGENICITY; JAPANESE (PEOPLE); LEUKOPENIA; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OROPHARYNX PAIN; PARENTERAL NUTRITION; PERIPHERAL MOTOR NEUROPATHY; PERIPHERAL NEUROPATHY; PERIPHERAL SENSORY NEUROPATHY; PHASE 1 CLINICAL TRIAL; PIGMENT DISORDER; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; SKIN PRURITUS; SODIUM DEFICIENCY; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 84943355374     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0243-5     Document Type: Article

References (21)

1. National Comprehensive Cancer Network (2014) Clinical practice guidelines in oncology: small cell lung cancer (version 1. 2015). http://www.nccn.org/professionals/physician-gls/pdf/sclc.pdf. Accessed 10 Nov 2014
2. Brahmer JR, Pardoll DM (2013) Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 1(2):85-91
3. Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R (2010) Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37(5):533-546
4. Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F (2012) The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 48(2):237-242
5. Pazdur R (2013) FDA Approval for Ipilimumab. National Cancer Institute at the National Institutes of Health. http://www.cancer.gov/cancertopics/druginfo/fda-ipilimumab. Accessed 19 Aug 2014
6. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2046-2054
7. Cancer Therapy Evaluation Program (2006) Common terminology criteria for adverse events (version 4.0). http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 9 Feb 2015
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
9. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E (2008) Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26(36):5950-5956
10. Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthy S, Wolchok JD (2013) Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 13:7
11. Clinicaltrials.gov (2011) Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC) http://clinicaltrials.gov/ct2/show/NCT01285609. Accessed 19 Aug 2014
12. Clinicaltrials.gov (2011) Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) http://clinicaltrials.gov/ct2/show/NCT01450761. Accessed 19 Aug 2014
13. Bristol-Myers Squibb (2011) Yervoy (ipilimumab) Risk Evaluation and Mitigation Strategy (REMS): Immune-mediated adverse reaction management guide. https://www.hcp.yervoy.com/pages/rems.aspx. Accessed 19 Aug 2014
14. Loprinzi CL, Messner C (2012) Understanding and managing chemotherapy side effects. Cancercare Connect booklet series. http://www.cancercare.org/publications/24-understanding-and-managing-chemotherapy-side-effect. Accessed 19 Aug 2014
15. King PD, Perry MC (2001) Hepatotoxicity of chemotherapy. Oncologist 6(2):162-176
16. Chemocare.com (2015) Hyperlipasemia (high blood lipase level). http://chemocare.com/chemotherapy/side-effects/hyperlipasemia-high-lipase.aspx#.U2zxEvldXxS. Accessed 19 Aug 19 2014
17. Feng Y, Roy A, Masson E et al (2013) Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 19: 3977-3986
18. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ (2013) Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 1291:1-13
19. Hoos A (2012) Evolution of end points for cancer immunotherapy trials. Ann Oncol 23(Suppl 8):viii47-52
20. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412-7420
21. Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, Muller PY, Frings W, Sims J (2010) Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2(3):233-255